Teduglutide (GLP-2): Evidence, Mechanism & Status

Teduglutide (Gattex in the US, Revestive in the EU) is a recombinant 33-amino-acid analog of glucagon-like peptide-2 (GLP-2), the intestinotrophic gut hormone that drives mucosal growth and absorptive adaptation. It is the first and best-evidenced growth-factor therapy for short bowel syndrome with intestinal failure — and it is also a frequent reference point in 'gut-repair' and leaky-gut conversations where its evidence does not reach.2 This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Teduglutide is a prescription biologic administered under specialist gastroenterology and nutrition-support supervision with mandatory endoscopic cancer surveillance. Dosing figures are reported strictly as published in trials and the FDA label for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is teduglutide and how does it work?

Teduglutide is a recombinant 33-amino-acid peptide analog of native human GLP-2. It differs from the endogenous hormone by a single substitution — glycine for alanine at position 2 of the N-terminus — which confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage and extends the half-life from native GLP-2's roughly 7 minutes to about 2 hours, enabling once-daily dosing.102

GLP-2 is secreted by enteroendocrine L-cells of the distal ileum and colon in response to luminal nutrients, and acts on GLP-2 receptors expressed on intestinal subepithelial myofibroblasts, enteric neurons and enteroendocrine cells. Receptor activation triggers downstream mediators — insulin-like growth factor-1 (IGF-1), nitric oxide and keratinocyte growth factor — that drive crypt-cell proliferation, reduce enterocyte apoptosis, and expand intestinal stem-cell and Paneth-cell populations.212 The net intestinotrophic effect is increased villus height and crypt depth — greater mucosal absorptive surface area — plus increased intestinal and portal blood flow, slowed gastric emptying and secretion, and strengthened tight-junction barrier integrity.1014 Administered subcutaneously, teduglutide reaches peak plasma concentration in roughly 3-5 hours. A useful pharmacodynamic confirmation of mucosal growth is plasma citrulline, a biomarker of functional enterocyte mass, which rises with treatment.7

What is the evidence by indication?

The headline contrast is that teduglutide is one of the few peptides in this encyclopedia with completed, pivotal human randomized controlled trials — but only for SBS-IF. The detailed trial registrations and protocols sit on ClinicalTrials.gov alongside the published reports below.

The adult Phase 3 data are the foundation. In Jeppesen's randomized, double-blind, placebo-controlled trial (n approximately 83, 24 weeks), clinical response — a >=20% reduction in parenteral support — reached 46% at 0.05 mg/kg/day versus 6% on placebo (p=0.005); the higher 0.1 mg/kg arm was not significantly different from placebo.12 STEPS, the largest double-blind randomized SBS-IF trial (n=86, 24 weeks), used a protocolized parenteral-support-reduction algorithm: 63% of teduglutide patients versus 30% of placebo achieved a 20-100% reduction in parenteral-support volume (p=0.002), with mean reduction of 4.4 L/week on teduglutide versus 2.3 L/week on placebo, and more patients achieving at least one day per week off parenteral support (54% versus 23%) — with no excess of serious adverse events.32

The long-term open-label extensions are what make the case clinically meaningful. Of 39 teduglutide patients followed through the 2-year STEPS-2 extension, 8 achieved full enteral autonomy — complete parenteral-support independence — with time-to-weaning of 28-115 weeks; lower baseline parenteral-support volume (<=9 L/week) and non-IBD etiology predicted weaning success.45 A one-year STEPS-3 extension showed durability in a small cohort.6

The pediatric Phase 3 (Kocoshis 2020) randomized children to two double-blind teduglutide doses plus a non-blinded standard-of-care arm (n=59). The primary endpoint of a >=20% parenteral-support reduction was met by 54.2% (0.025 mg/kg), 69.2% (0.05 mg/kg) and just 11.1% (standard of care), with both doses significantly reducing parenteral-support volume, calories and infusion days, and raising plasma citrulline; enteral autonomy occurred in 8.3% and 11.5% of the dose groups versus 0% of standard of care.78 Retrospective real-world series corroborate the trial efficacy, with roughly 67% achieving a >=20% reduction and about 30% reaching enteral autonomy.9

What doses appear in the literature?

Reported strictly as information, not a protocol. Per the FDA label and pivotal trials, the dose is 0.05 mg/kg subcutaneously once daily, into alternating sites (thigh, arm and abdominal quadrants), reconstituted from lyophilized powder per the supplied diluent and Instructions for Use.1510 For moderate-to-severe renal impairment (CrCl <=50 mL/min) or end-stage renal disease, a 50% dose reduction applies.15 Pediatric dosing for children >=1 year uses the same weight-based 0.05 mg/kg/day, although the pediatric RCT also tested a lower 0.025 mg/kg/day arm.7 The dose-finding work established 0.05 mg/kg/day as optimal; the higher 0.10 mg/kg/day arm did not consistently reach statistical significance.2 Treatment requires a baseline colonoscopy or upper-GI endoscopy with polyp removal within 6 months of starting, plus periodic biliary and pancreatic labs, and reassessment of parenteral-support volume as absorption improves to avoid fluid overload.18

How safe is teduglutide?

The principal warning is accelerated neoplastic growth. Because teduglutide is intestinotrophic, it can promote hyperplastic or neoplastic change: intestinal polyps occurred in trials, and postmarketing reports include colorectal, gastric and small-intestinal polyps. The label mandates colonoscopy or upper-GI endoscopy before treatment, at about 1 year, then roughly every 5 years (or more often), with discontinuation if colorectal or small-bowel cancer is diagnosed.1517 Other warnings include intestinal or stomal obstruction, biliary and pancreatic disease (cholecystitis, cholangitis, cholelithiasis, pancreatitis), and fluid overload as absorption improves and parenteral fluid must be down-titrated.15 Because it enhances mucosal absorption, teduglutide can increase uptake of concomitant oral drugs — a caution with narrow-therapeutic-index agents.15

The most common adverse reactions across trials and the label are abdominal pain and distension, nausea, vomiting, headache, injection-site reactions, peripheral edema, and — in stoma patients — gastrointestinal stoma complications; in the pediatric Phase 3 the most common treatment-emergent events were pyrexia and vomiting.715 Active gastrointestinal malignancy is an effective contraindication, and in patients with active non-GI malignancy or a history of GI cancer it is used only when benefit clearly outweighs risk.15

What is the FDA and WADA status in 2026?

Teduglutide is an approved biologic, not a research chemical. Gattex was approved December 21, 2012 for adults with parenteral-support-dependent SBS and expanded in 2019 to pediatric patients aged 1 year and older; label revisions through 2024 retain the neoplasia-surveillance and obstruction and biliary warnings.1516 It is orphan-drug designated, marketed by Takeda with a REMS-style safety program, and approved as Revestive in the EU and additional markets; regional pediatric and infant studies continue.172021 Because it is a defined, commercially available branded product, there is no evidence-based or regulatory basis for compounding it as a research peptide; any 'research-chemical' GLP-2 sold outside the approved supply chain is unapproved and unverified.

For athletes, teduglutide is not explicitly named on the WADA Prohibited List. It is a gut-restricted intestinotrophic agent with no recognized ergogenic or anabolic-systemic action — unlike GLP-1 agonists, which WADA placed on its Monitoring Program, GLP-2 analogs are not flagged as performance-relevant. Athletes with a medical need should still verify current status with their anti-doping authority.19

Bottom line. Teduglutide is a genuine, RCT-proven, disease-modifying therapy — but for a narrow population: short bowel syndrome with intestinal failure dependent on parenteral support, where the evidence is Grade A and biomarker-confirmed. The trade-off is a serious, label-mandated surveillance burden for accelerated neoplastic growth plus obstruction, fluid-overload and biliary/pancreatic risks, making it a specialist-managed drug rather than a casual gut-repair peptide. Its barrier-strengthening biology is frequently cited in leaky-gut and IBD conversations, but that application is Grade C — promising in principle, unproven in humans outside SBS. Regulatory facts here are current as of June 2026 and should be re-verified against the latest FDA label and WADA list.